Pfizer Launches Platform, Competes with Eli Lilly
Pfizer Launches Platform, Competes with Eli Lilly

Pfizer Launches Platform, Competes with Eli Lilly

News summary

Pfizer has launched a direct-to-consumer (D2C) digital platform, PfizerForAll, aimed at patients with migraines and respiratory ailments, including COVID-19. This move puts Pfizer in direct competition with Eli Lilly, which has recently introduced a new, more affordable version of its weight-loss drug Zepbound in single-dose vials, priced at about half the cost of its previous offerings. Lilly's strategy aims to overcome supply chain issues related to its complex auto-injector pens and to compete with compounded versions of GLP-1 drugs. The new pricing structure for Zepbound has led to a significant decline in shares of competitors like Viking Therapeutics and Zealand Pharma. Lilly's initiative is expected to increase consumer access and affordability, addressing a critical gap for patients without insurance coverage. Analysts consider Lilly's move a strategic challenge to the existing compounded drug market, potentially increasing market pressures on similar players such as Hims&Hers Health.

Story Coverage
Bias Distribution
71% Left
Information Sources
d387b58c-602b-49e7-8f0e-990aad2baa4709bc43f5-e425-4ffd-980d-14d8f4a28792a8525413-d1cb-4a36-b99e-5987ae74bd3171639883-fbbd-48af-8cc3-393f63e7b2ef
+10
Left 71%
Center 21%
R
Coverage Details
Total News Sources
14
Left
10
Center
3
Right
1
Unrated
0
Last Updated
83 days ago
Bias Distribution
71% Left

Open Story Timeline

Story timeline 1Story timeline 2Story timeline 3Story timeline 4Story timeline 5Story timeline 6Story timeline 7Story timeline 8Story timeline 9Story timeline 10Story timeline 11Story timeline 12Story timeline 13Story timeline 14

Analyze and predict the
development of events

Related News
Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Related News
Recommended News